A study of JZP150 in adults with posttraumatic stress disorder

Study status: Completed

JZP150 is an oral, highly selective inhibitor of fatty acid amide hydrolase (FAAH). In this phase 2 study, participants with PTSD will receive either placebo or 1 of 2 doses of JZP150. The primary objective of the study will assess the change in PTSD symptoms from baseline to Week 12 using the Clinician Administered PTSD Scale (CAPS-5).

Participation criteria
Conditions & interventions
More information

Sex: All
Minimum age: 18 Years
Maximum age: 70 Years

Researchers look for people who fit a certain description, called eligibility criteria. Below are the inclusion and exclusion criteria for study participants:

Inclusion criteria

Participants aged 18 to 70 years
Participants must be outpatients with a primary diagnosis of Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) defined PTSD confirmed by the clinical interview
PTSD is primary diagnosis

Exclusion criteria

Acute or unstable medical condition, behavioral or psychiatric disorder (other than PTSD)
Suicidal behavior in the past 2 years or active suicidal ideation in the past 6 months
Ongoing traumatic event or exposure to a traumatic event <3 months prior to Screening
Index event > 12 years
Index event is combat trauma

Conditions

Post traumatic stress disorder

Intervention/treatment

Drug: JZP150
Drug: Placebo

Sponsor

Jazz Pharmaceuticals

Phase

Phase 2